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Chimeric antigen receptor T-cell (CAR-T) therapy is an effective new treatment for hematologic malignancies. Two anti-CD19 CAR-T 
products, namely axicabtagene ciloleucel and tisagenlecleucel, have been approved for the management of relapsed/refractory large 
B-cell lymphoma after two lines of systemic therapy. Additionally, tisagenlecleucel is indicated for refractory acute lymphoblastic 
leukemia in pediatric patients and young adults up to 25 years of age. CAR-T cells are undoubtedly a major breakthrough therapy 
in hematooncology resulting in up to 90% response rate with durable remissions in population with refractory high-risk disease. 
However, there are serious side effects resulting from CAR-T therapy, including cytokine release syndrome (CRS) and immune effector 
cell-associated neurotoxicity syndrome (ICANS). Manifestations of CRS mostly include fever, hypotension, hypoxia, and end organ 
dysfunction. Neurologic toxicities are diverse and include encephalopathy, cognitive defects, dysphasia, seizures, and cerebral edema. 
Since the symptoms are potentially severe, practitioners need to familiarize themselves with the unique toxicities associated with these 
therapies. In this article, we present a practical guideline for diagnosis, grading and management of CRS and CAR-T neurotoxicity. In 
addition, infectious complications and late toxicities including prolonged cytopenias and hypogammaglobulinemia are discussed.
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Chimeric antigen receptor T (CAR-T) cells can produce durable 
remission in hematological malignancies, not responding to standard 
therapy. In the setting of aggressive lymphoma, two CAR-T products 
are currently commercially available, namely, axicabtagene ciloleucel 
(Yescarta, Gilead/Kite), and tisagenlecleucel (Kymriah, Novartis). 
The treatment with CAR-T cell is associated with unique array 
of toxicities, which may limit its use. On the basis of registration 
studies, the most common complications include cytokine release 
syndrome (CRS), neurotoxicity now referred as immune effector 
cell-associated neurotoxicity syndrome (ICANS), infections, tumor 
lysis syndrome, allergic reactions, prolonged neutropenia, and 
hypogammaglobulinemia. Herein, we present current management 
recommendations concerning CRS, ICANS, and infections (including 
also prolonged neutropenia or hypogammaglobulinemia).
Cytokine release syndrome
CRS is the most common complication observed after CAR-T cells 
infusion. In the registration study ZUMA-1, CRS occurred in 93% of 
patients, in JULIET study in 67% of patients; however, grade 3–4 was 
seen in about 11%. The time of appearance of CRS is 2 (1–12) days 
with an average duration of 3 days for Yescarta and 3 (1–10) days and 
7 days duration for Kymriah [1, 2]. The diagnosis of CRS is primarily 
based on clinical assessment. There are four main symptoms of CRS, 
namely, fever, hypotension, hypoxia, and end organ toxicity (Tab. I) [3, 4]. 
The intensity of CRS can be determined by grading system – currently 
recommended ASTCT (American Society for Transplantation and 
Cellular Therapy) grading system replaced previously used Lee 
grading model, UPenn scale, MSKCC criteria, or CARTOX [4]. Clinical 
symptoms and signs of CRS with grading model are presented 
in table I [5].
CRS is a generalized immune response with positive feedback 
between cytokines and immune system cells and is potentially 
fatal complication. CRS was first described by John Ferrara over 
25 years ago in patients after allogeneic stem cell transplantation 
with graft versus host disease. It can also be observed in a course 
of Ebola fever, influenza, smallpox, and acute respiratory distress 
syndrome. After CAR-T therapy, the cytokines implicated in CRS 
are directly produced by infused CAR-T cells (activated when their 
CARs engage the designated antigen), macrophages/monocytes, 
and dendritic cell. Serum concentrations of wide variety of cytokines 
include interlekin-1 (IL-1), interleukin-6 (IL-6), soluble IL-6 receptor, 
interleukin-2 (IL-2), soluble receptor IL-2, tumor necrosis factor 
alfa (TNF-a), interleukin-10 (IL-10), interleukin-8 (IL-8), interferon 
gamma (IFN-g), monocytes chemoattractant protein 1 (MCP-1), 
granzyme B, and soluble gp130 increase, which can be related to CRS 
severity. Predictive factors for CRS include three main groups [6, 7]:
• Patient-related factors: infection or inflammatory state, HCT-CI 
index
• Tumor-related factors: disease type, tumor burden
• CAR-T related factors: CAR-T cell design (costimulatory domain 
use) and number in the product
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New predictive markers are being sought to predict and monitor 
CRS more precisely. Current CRS monitoring markers in clinical 
practice include ferritin, C-reactive protein (CRP), IL-6, IFN-g. Ferritin 
and CRP are the most relevant due to the availability and speed of 
determination.
Recommendation
•  CAR-T cells should not be administered in case of symptoms of 
infection. In the case of infection, administration of the product 
should be postponed.
•  Patient should be monitored daily for the first 10 days following 
CAR-T infusion for signs and symptoms of potential CRS.
•  After the first 10 days, the patient should be monitored at the 
physician’s discretions. Patient should be instructed to remain 
within proximity of the hospital for at least 4 weeks following 
infusion.
•  To confirm the diagnosis of CRS, other causes of systemic 
inflammatory response must be excluded, including infections. In 
the case of neutropenic fever or documented infection treatment 
with broad-spectrum antibiotics, fluids, and maintenance 
treatment must be used in accordance with the existing medical 
indications.
•  Therapy of CRS is related to its grade and includes symptomatic 
treatment, tocilizumab and corticosteroids. Details are described 
in table I. From grade 3, treatment on intensive care unit (ICU) is 
recommended.
–  Grade 1 – only symptomatic treatment: pain killers, anti-
emetics, antipyretics, sedatives, and so on.
–  Grade 2 – symptomatic treatment: fluid therapy, oxygen therapy 
+ tocilizumab at a dose of 8 mg/kg intravenously for 1 hour (do 
not exceed the dose of 800 mg). If there is no improvement, low 
RR or oxygen demand increases, repeat the dose every 8 h, up 
to a maximum of 4 doses. When there is no improvement after 
24 h,  treatment as in Grade 3 is recommended.
–  Grade 3 – symptomatic treatment: fluid therapy, oxygen 
therapy + tocilizumab every 8 h. Do not give more than 3 
doses in 24 h; the maximum total number of doses is 4, if no 
clinical improvement in the signs and symptoms of CRS, give 
methylprednisolone, intravenously at a dose of 1 mg/kg twice 
daily or an equivalent dose of dexamethasone (e.g., 10 mg 
intravenously every 6 h). Continue corticosteroid treatment until 
the event is classified as a grade 1 or less event, then gradually 
reduce the dose over 3 days. If there is no improvement, apply 
treatment as per grade 4. Grade 3 of CRS require treatment 
on ICU.
–  Grade 4 – treatment as in grade 3 + methylprednisolone 
intravenously at a daily dose of 1000 mg for 3 days, when 
there is improvement continue treatment as in grade 3, in 
the absence of improvement or deterioration consider other 
immunosuppressive drugs.
•  The possibility of haemophagocytic lymphohistiocytosis/
macrophage activation syndrome (HLH/MAS) or infections 
should be considered in patients with severe or nonresponsive 
CRS treatment.
Tocilizumab is a recombinant humanized monoclonal antibody 
directed against the IL-6 receptor, registered for the treatment of 
patients with systemic connective tissue diseases. The drug blocks 
the signal transmission through the IL-6 receptor, thus inhibiting 
the inflammatory reaction. Tocilizumab induces the rapid reversal 
of CRS and has become the standard of care for this complication. 
Corticosteroids suppress the inflammatory reaction in patients not 
responding to IL-6 receptor blockade. Preliminary results suggest 
that the use of IL-6 receptor blockade or steroids is not associated 
with higher rate of lymphoma relapse compared with patients without 
CRS after CAR-T. New drugs blocking the signal pathways in CRS are 
being tested. These drugs include siltuximab – monoclonal antibody 
anti-lL-6, anakinra – human interleukin-1 receptor antagonist, 
tyrosine kinase inhibitor – dasatinib, adenosine A3 receptor agonists, 
JAK-STAT inhibitors (namodenosone, piclidenosome), lenzilumab –
monoclonal antibody anti-GM-CSF.
Immune effector cell-associated neurotoxicity 
syndrome
Immune effector cell-associated neurotoxicity syndrome (ICANS) is 
the second most common acute toxicity observed with CAR-T cell 
therapy. The rate of ICANS of any grade associated with CD19-
targeted CAR-T cell therapy in patients with lymphoma ranges 
from 23% to 67%, with grade 3–4 seen in 12–30% [3, 4, 7]. It may 
Table I. ASTCT CRS consensus grading [5]
CRS Grade Defining Features of Grade
Grade 1 Temperature ≥38°C
Hypotension: none
Hypoxia: none
Grade 2 Temperature ≥38°C
Hypotension: not requiring vasopressors
Hypoxia: requiring low-flow nasal cannula (oxygen ≤ 6 L/min) or blow-by
Grade 3 Temperature ≥38°C
Hypotension: requiring a vasopressor with or without vasopressin
and/or
Hypoxia: requiring high-flow nasal cannula (oxygen > 6 L/min), facemask, nonrebreather mask or Venturi mask
Grade 4 Temperature ≥38°C
Hypotension: requiring multiple vasopressors (excluding vasopressin)
Hypoxia: requiring positive pressure (e.g. CPAP, BiPAP, intubation and mechanical ventilation)
Organ toxicities associated with CRS may be graded according to CRCAE v5.0 but do not influence CRS grading. Fever is defined as ≥38°C not attributable to 
any other cause.
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manifest with a wide variety of symptoms, with the most typical 
encephalopathy with word-finding difficulty, aphasia, and confusion. 
All neurologic and psychiatric adverse reactions reported in clinical 
trials with currently approved CAR-T products are listed in table II. 
Symptoms of ICANS usually occur few days later than symptoms 
of CRS, but may also occur simultaneously. Very rarely, neurologic 
toxicities occur in patients who do not have typical signs of CRS. 
Symptoms of ICANS have been reported to occur 1 day after CAR-T 
cell infusion, to the third or fourth week after infusion.
The pathophysiology of neurotoxicity is not well understood, as 
it is for CRS. Similar to CRS, severity of ICANS is associated with 
patient-specific and tumor factors, including underlying diagnosis, 
disease burden, pre-existing neurologic comorbidities, treatment 
history, and patient age. High tumor burden and inflammatory state 
are associated with more severe toxicity. In addition treatment-
related factors, like intensity of lymphodepleting therapy, high CAR-T 
cell dose, and CAR-T design may also be associated with its severity. 
Higher neurologic toxicity grade has been observed to be associated 
with higher grade CRS, suggesting an independent mechanism for 
each process, but the similar causes. Severe neurologic toxicity 
is associated with peak blood CRP, early peak of IL-6, and higher 
blood levels of multiple serum cytokines. Elevated concentration 
of proteins and cytokines in cerebrospinal fluid (CSF) may reflect 
enhanced blood/brain barrier permeability which allow CAR-T cells 
to penetrate central nervous system (CNS). Given all the above, it 
could be hypothesized that ICANS is caused by the same factors as 
CRS, but delayed clinical neurological presentation is due to initial 
integrity of the blood/nerve or blood/brain barrier respectively which 
becomes subsequently disrupted [8]. Like CRS, ICANS is completely 
reversible in most of patients and tends to have a self-limited course. 
The recommended grading ASTCT model for neurotoxicity is 
presented in tables III and IV.
Recommendation
•  Patients with a CNS disorder are likely to be more vulnerable 
to develop neurologic events after CAR-T and require special 
attention.
•  The experience of use of CAR-T cells in patients with primary or 
secondary CNS lymphoma is limited, and thus the risk/benefit 
has not been established in this population.
•  Patient should be monitored daily for the first 10 days following 
CAR-T infusion for signs and symptoms of potential neurologic 
events.
•  After the first 10 days, the patient should be monitored at the 
physician’s discretions. Patient should be instructed to remain 
within proximity of the hospital for at least 4 weeks following 
infusion.
•  In case of neurotoxicity grades 1 and 2 imaging of the brain 
(MRI or in the absence CT) to rule out cerebral edema and 
electroencephalogram to exclude electrical seizures should 
be done. Levetiracetam in a dose of 500 mg twice daily is 
recommended as seizure prophylaxis, started on the day of 
infusion or after the onset of ICANS.
Table II. Neurologic and psychiatric adverse reactions reported with approved CAR-T [5]
Tisagenlecleucel (Kymriah) Axicabtagene ciloleucel (Yescarta)
Encephalopathy: includes cognitive impairment, confusional state, depressed 
level of consciousness, attention disturbances, mental status changes, somno-
lence, and automatisms
Delirium: includes delirium, agitation, hallucination, visual hallucinations, 
irritability, and restlessness
Headache: includes headache and migraine
Anxiety
Sleep disorder: includes sleep architecture disturbances, insomnia, and night-
mares 
Encephalopathy: includes encephalopathy, cognitive impairment, confusional 
state, depressed level of consciousness, disturbed attention, hypersomnia, leu-
koencephalopathy, mental status changes, paranoia, somnolence, and stupor
Delirium: includes agitation, delirium, delusion, disorientation, hallucination, 
hyperactivity, irritability, and restlessness
Headache
Dizziness: includes balance disturbances, presyncope, and syncope
Aphasia: includes sensory and/or motor aphasia/dysphasia






Table III. ASTCT ICANS consensus grading [5]
ICANS Grade Defining Features of Grade
Grade 1 • ICE score 7‐9 and/or depressed level of consciousness but awakens spontaneously
• No seizures, motor weakness, or raised ICP/cerebral edema
Grade 2 • ICE score 3‐6 and/or depressed level of consciousness but awakens to voice
• No seizures, motor weakness, or raised ICP/cerebral edema
Grade 3 • ICE score 0‐2 and/or depressed level of consciousness but awakens to tactile stimulus
• Any clinical seizure focal or generalized that resolves rapidly, or nonconvulsive seizures on EEG that resolve with intervention
• No motor weakness
• Focal/local edema on neuroimaging
Grade 4 • ICE score 0 and patient is unarousable or requires vigorous or repetitive tactile stimuli to arouse or stupor or coma
• Life‐threatening prolonged seizure (>5 min); or repetitive clinical or electrical seizures without return to baseline in between
• Deep focal motor weakness such as hemiparesis or paraparesis
• Diffuse cerebral edema on neuroimaging; decerebrate or decorticate posturing; or cranial nerve VI palsy; or papilledema; or Cushing’s triad
ICE – immune effector cell‐associated encephalopathy; ICP – intracranial pressure.
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•  Patients with grade 2–3, ICANS should be treated with 
dexamethasone in a dose 10 mg intravenously every 6 hours 
until Grade 1, then taper over 3 days. Levetiracetam should be 
given as seizure prophylaxis.
•  Grade 4 is an indication to treatment on the intensive care unit with 
and high dose of methylprednisolone 1000 mg per day, for 3 days. 
Intubation and mechanical ventilation should be considered. 
Levetiracetam should be given as seizure prophylaxis. Patients 
with cerebral edema should be managed with hyperventilation, 
hyperosmolar therapy (mannitol or hypertonic saline) to decrease 
intracranial pressure, in rare cases ventriculo-peritoneal shunt 
may be adequate treatment. Levetiracetam, phenobarbital, 
valproate acid and/or lacosamide should be added in case 
of seizures. For short-term control, benzodiazepines may be 
used; EEG monitoring seems to be useful only in patients with 
remitting confusion or deeply unconscious as they may develop 
respectively nonconvulsive epileptic seizures or nonconvulsive 
epileptic state.
•  Tocilizumab is recommended only if CRS simultaneously 
occurred.
Infectious complications
Infectious complications may occur after CAR-T therapy as early or 
late events. The incidence of these infections is similar to the incidence 
after other salvage chemoimmunotherapy. Predisposing factors for 
its development include poor immune function related to malignancy 
and prior cytotoxic treatment, cytopenia after lymphodepleting 
chemotherapy, use of corticosteroids or tocilizumab, stay on ICU, 
hypogammaglobulinemia [9].
Early infections, up to 30 days, are related mainly to neutropenia and 
are seen in about 23% of patients, based on clinical trials. Most of 
infections, 80%, occur within the first 10 days, with median 6 (1–27) 
days from CAR-T cell infusion. Bacteria are the most common 
pathogen, identified in 17% of patients, mainly as bacteriemia. 
Viruses, mostly respiratory virus infections, are responsible for 
about 9% of infections, and fungal infections are rare events (4%). 
In about 19% of cases, febrile of unknown origin is seen and can be 
concurrent with CRS. Most of early infections are mild or moderate. 
The main risk factor for infection development after CAR-T cell 
infusion is severity of CRS [10].
Between days 30 and 90 after CAR-T infusion, infectious complication 
is seen in about 14% and is related to hypogammaglobulinemia, 
prolonged neutropenia (22%) or persistent disease (48%). Viral 
infections are the most common (respiratory virus infections), 
followed by bacterial etiology. Invasive fungal infections are observed 
in high-risk patients with previous allogeneic stem cell transplantation 
or prolonged corticosteroids therapy.
After day 90, post CAR-T cell administration infections are rare, mild, 
and treated usually in the outpatient setting. Hypogammaglobulinemia 
is the most common late event; however, about 16% of patients 
experience prolonged neutropenia.
Recommendation
•  CAR-T cells should not be administered in case of symptoms of 
infection. In the case of infection, administration of the product 
should be postponed.
•  Patient should be monitored daily for the first 10 days following 
CART infusion for signs and symptoms of potential infections.
•  After the first 10 days the patient should be monitored at the 
physician’s discretions. Patient should be instructed to remain 
within proximity of the hospital for at least 4 weeks following 
infusion.
•  Total serum IgG concentration should be checked prior to and 
in monthly intervals after CAR-T infusion for at least 3 months.
•  IgG replacement should be considered in patients with IgG 
< 400 mg/dl and serious, persistent, or recurrent bacterial 
infections.
• Prophylaxis includes
–  Antibacterial – fluorochinolones during neutropenia can be 
considered according to center policy.
–  Antiviral – acyclovir or valcyclovir for 1 year in seropositive 
patients.
–  Antifungal – for low risk patients fluconazole or micafungin 
during neutropenia; for high-risk patients posaconazole 
or voriconazole (prolonged neutropenia, steroids, prior 
alloHCT).
–  Pneumocystis jiroveci – cotrimoxazole from day 28 for 
6 months.
–  Vaccinations – live vaccines are contraindicated 6 weeks prior 
to CAR-T therapy; no data regarding re-vaccination (suggested 
transplant-like protocol).
•  Fever of unknown origin should be treated with broad-spectrum 
antibiotics, fluids, and other supportive care
•  Documented infections should be treated with antibiotics 
according to general and/or institutional guidance
•  Prolonged neutropenia may be treated with G-CSF; however 
autologous (or allogeneic if prior allogeneic stem cell 
transplantation) stem cell infusion can be considered.
Summary
CAR-T cells is definitely breakthrough therapy changing the 
landscape of treatment of refractory B-cell malignancies. Definitely the 
indications for CAR-T cells will be quickly expanded, and the usage 
Table IV. Encephalopathy assessment tools for grading of ICANS [5]
ICE – immune effector cell‐associated encephalopathy 
• Orientation: orientation to year, month, city, hospital: 4 points
• Naming: ability to name 3 objects (eg, point to clock, pen, button): 3 points
• Following commands: ability to follow simple commands (eg, “Show me 2 fingers” or “Close your eyes and stick out your tongue”): 1 point
• Writing: ability to write a standard sentence (eg, “Our national bird is the bald eagle”): 1 point
• Attention: ability to count backwards from 100 by 10: 1 point
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of this technology will become more common. Enthusiastic results 
are associated with unique, potentially fatal toxicities. Clinical and 
laboratory monitoring for CRS and ICANS after CAR-T is imperative 
for early diagnosis and treatment to avoid early mortality. Grading 
of severity of these side effects is an essential part of the treatment 
algorithms and needs to be unified. Tocilizumab and corticosteroids 
remain the mainstay of the treatment currently. Cytopenias, 
hypogammaglobulinemia, and infections are also important to be 
diagnosed and treat as clinically indicated. The CAR-T technology 
is developing extremely quickly, and new data from conducted 
clinical trials will certainly change the algorithms of diagnostic and 
therapeutic procedures.
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